Poster Session I - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P463 - ESOC25-2074 PLASMA PTAU217 AS A BIOMARKER FOR POST-STROKE COGNITIVE IMPAIRMENT PREDICTION: A NESTED CASE-CONTROL STUDY Elena Escriche 1 , Mara Molina 1 , Mnica Macas 2 , Inhar Esnaola 1 , Adrin Jimnez 1 , Miren Roldan 2 , Amaya Urdnoz-Casado 2,3 , Nuria Sobrino 4 , Celia Fernndez 4 , Idoia Rubio 1 , Roberto Muoz 1,3 , Maria Herrera Isasi 1,3 , Maite Mendioroz 1,2,3 1 Neurology Department, University Hospital of Navarra, Pamplona, Spain, 2 Neuroepigenetics Unit, Navarrabiomed-UPNA, Pamplona, Spain, 3 Redes de Investigacin Cooperativa Orientadas a Resultados en Salud (RICORS)- ISC III, Madrid, Spain, 4 Radiology Department, University Hospital of Navarra, Pamplona, Spain Background and Aims: Post-stroke cognitive impairment (PSCI) represents a significant complication affecting stroke survivors
Timing: Dosing is most often administered in the evening, shortly before bedtime, to align with its hypothesized promotion of SWS and natural circadian rhythms
regulation and medical practice
[DOI] [PubMed] [Google Scholar] 135.Anisman H., Hayley S., Turrin N., Merali Z
